DE19523660A1 - Antigens with characteristics of retro-virus - Google Patents
Antigens with characteristics of retro-virusInfo
- Publication number
- DE19523660A1 DE19523660A1 DE1995123660 DE19523660A DE19523660A1 DE 19523660 A1 DE19523660 A1 DE 19523660A1 DE 1995123660 DE1995123660 DE 1995123660 DE 19523660 A DE19523660 A DE 19523660A DE 19523660 A1 DE19523660 A1 DE 19523660A1
- Authority
- DE
- Germany
- Prior art keywords
- virus
- antigens
- paga
- retro
- immune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1247—DNA-directed RNA polymerase (2.7.7.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Die Immunschwäche Aids ist durch ausgeprächte Immun suppression gekennzeichnet, die klinisch mit opportunis tischen Infektionen, Degenerationen im Zentralnervensys tem und malignen Tumoren einhergeht. Das Krankheitsbild wird durch ein Virus (Retrovirade) verursacht, daß Tumor zellen und Makrophagen befällt. Die beim Menschen be kannten HIV-Typen unterscheiden sich im Genom und in der Antigenizität, lösen aber klinisch gleiche Krankheits bilder aus.The immune deficiency AIDS is due to pronounced immune suppression characterized clinically with opportunis infections, degenerations in the central nervous system and malignant tumors. The clinical picture is caused by a virus (retrovirade) that tumor cells and macrophages. The human be Known HIV types differ in genome and in Antigenicity, but solve clinically the same disease pictures from.
Das Genom besteht aus 2 identischen RNS-Strängen. Es ist
zusammen mit den beiden Enzymen "Reverse Transkriptase"
und der "Interase" von einem sog. Kapsid umgeben.
Dieses Kapsid ist in von der Wirtszelle stammende
Phospholipidmembran eingepackt. In dieser Hülle ist
jenes genetische Material integriert, daß den Ablauf
der HIV-Infektion bestimmt!
In einem ersten Schritt kommt es zu einer hochaffinen
Bindung an CD4-Moleküle, die von T-Zellen und Makrophagen
exprimiert werden, worauf es zur Infektion dieser Zellen
führt. Nach dem Eindringen des Virus werden die Enzyme
des Nukleoproteinkomplexes aktiv, wonach die Reproduktion
des Virus einsetzt.The genome consists of 2 identical RNA strands. Together with the two enzymes "reverse transcriptase" and the "interase" it is surrounded by a so-called capsid. This capsid is packaged in phospholipid membrane derived from the host cell. The genetic material that determines the course of HIV infection is integrated in this shell!
The first step is high-affinity binding to CD4 molecules that are expressed by T cells and macrophages, which leads to infection of these cells. After the virus penetrates, the enzymes of the nucleoprotein complex become active, after which the reproduction of the virus begins.
Das Hauptproblem liegt daran, daß die HIV-Infek tion die komplexen Wechselbeziehungen zwischen den Effekten des Virus auf die Funktion den immunkomponennten Zellen und der Immunantwort des Wirts auf das Virus widerspiegelt, und mit indirekten Mechanismen die noch nicht infizierten Zellen des Immunsystems außer Betrieb setzt. Da das Virus von Zelle zu Zelle überspringen kann können sich Antikörper, die nicht auswechselbaren Abschnitte des Virus erkennen, die Fusion bloc kieren und freie Viruspartikel neutralisieren, als nützlich erweisen.The main problem is that the HIV infection tion the complex interrelations between the effects of the virus on the function immune component cells and the immune response of the host reflects on the virus, and with indirect mechanisms that are not yet infected Immune cells of the immune system. Because the virus can jump from cell to cell can become antibodies that are not interchangeable Detect sections of the virus that merge bloc and neutralize free virus particles, prove useful.
Die Prozesse zur Nachlassung der Aktivität von Symptomen die mit dem HIV assoziieren, zeigten keinen Erfolg. (Klasse A 61 K, Gruppe 39/00, Intern. Kl - Nr. WO 89/02749). Auch andere Vakzine und Therapien gaben keine Lösungen. (Aids vom Molekül zur Pandemie, von Michael C. Koch 1989 Heidelberg Spektrum des Wissens-Verlag Ges. 1989 ISBN 3-922508-9).The processes to decrease the activity of Symptoms associated with HIV showed no success. (Class A 61 K, group 39/00, Intern. Kl No. WO 89/02749). There were also no other vaccines and therapies Solutions. (AIDS from molecule to pandemic, by Michael C. Koch 1989 Heidelberg Spectrum of Wissens-Verlag Ges. 1989 ISBN 3-922508-9).
Das HIV besitzt eine Schwachstelle! Diese ist in der Genetik zu finden. Damit sich das Virus trans kriptieren und vermehren kann, muß es das Phospho lipidmembran verlassen und das Kapsid öffnen. Danach wird es lysiert.HIV has a weak point! This is in to find genetics. So that the virus trans script and multiply, it must be the phospho Leave the lipid membrane and open the capsid. Then it is lysed.
Dieses "Lysieren" ist sein Schwachpunkt, wo PagA sich einsetzt! This "lysing" is its weak point where PagA is committed!
Das PagA wirkt gegenüber dem Immunsystem anti thetisch. Ferner besitzt es adequante Charakteren mit dem Virus. So paßt sich PagA dem Virus an und geht in einer hochaffinen Bindung mit das Virus einher. Dabei wird das Enzym "Reverse Transkriptase" gegen den Nukleinsäurepolymorphismus von PagA umgetauscht. Somit wird die virale DNS wieder in RNS übersetzt. Das Virus wird wieder lysiert. Nun wird mit der Proteinbiosynthese des PagA der genetische Cod des Virus verändert, wobei die Translation des PagA behilflich ist.The PagA has an anti-immune effect thetic. It also has adequate characters with the virus. So PagA adapts to the virus and goes in a high affinity bond with the virus hand in hand. The enzyme "reverse transcriptase" against the nucleic acid polymorphism of PagA exchanged. Thus the viral DNA is again in RNA translated. The virus is lysed again. Well now with the protein biosynthesis of PagA the genetic Cod of the virus changed, the translation of the PagA is helpful.
Das Virus ist nun völlig zerstört!
Die Zellhybride aus der Fl-Generation (PagA+HIV)
werden zusammen mit den freigesetzten Viruspar
tikel völlig entfernt.The virus is now completely destroyed!
The cell hybrids from the Fl generation (PagA + HIV) are completely removed together with the released virus particles.
PagA kann nicht bei einem intakten Immunsystem ein gesetzt werden, da es durch Antikörper (meist IgM) zerstört wird. Bei Krebsbehandlungen empfiehlt sich die Impfung direkt in der Metastase.PagA cannot respond to an intact immune system as it is caused by antibodies (mostly IgM) gets destroyed. Cancer treatments are recommended vaccination directly in the metastasis.
Bereits 1982 hatte ich damit Erfolg. Bei stationärer Behandlung meiner Appendizitis (Blinddarm war 12 Std. vor Krankenhauseinlieferung durchgebrochen) fanden die Ärzte 2 Narben im Magen. Hierbei wurde der Verdacht auf Krebs gesetzt. Die Heilung ist den Ärzten unklar. Antikörper wurden nicht festgestellt. Somit verdanke ich PagA mein Leben!I had success with this back in 1982. With inpatient treatment of my appendicitis (Appendix was 12 hours before hospital admission the doctors found 2 scars in the stomach. Here, suspicion of cancer was raised. The Healing is unclear to the doctors. Antibodies were not found. So I owe PagA mine Life!
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1995123660 DE19523660A1 (en) | 1995-06-29 | 1995-06-29 | Antigens with characteristics of retro-virus |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1995123660 DE19523660A1 (en) | 1995-06-29 | 1995-06-29 | Antigens with characteristics of retro-virus |
Publications (1)
Publication Number | Publication Date |
---|---|
DE19523660A1 true DE19523660A1 (en) | 1997-01-02 |
Family
ID=7765557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE1995123660 Withdrawn DE19523660A1 (en) | 1995-06-29 | 1995-06-29 | Antigens with characteristics of retro-virus |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE19523660A1 (en) |
-
1995
- 1995-06-29 DE DE1995123660 patent/DE19523660A1/en not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69027187T2 (en) | METHOD FOR INACTIVATING VIRUSES IN VIRUS POLLUTED PHARMACEUTICAL COMPOSITIONS | |
DE69632395T2 (en) | COCHLEATE DELIVERY VALVE FOR BIOLOGICALLY RELEVANT MOLECULES | |
DE69519670T2 (en) | MICROPARTICLE WITH DELIVERY SYSTEM | |
EP3413907B1 (en) | Blood treatment with inactivation of circulating nucleic acids | |
JP6109881B2 (en) | Method for reducing the viral and microbial content of a solid-containing biological extract | |
DE69936337T2 (en) | METHOD FOR DEVELOPING AN HIV VACCINE | |
CN101790377A (en) | Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent | |
DE60315636T2 (en) | BACTERIOPHAGES SUITABLE FOR THE THERAPY AND PROPHYLAXIS OF BACTERIAL INFECTIONS | |
DE3019847C2 (en) | Process for the production of human interferon | |
DE68909100T2 (en) | Physiologically active substances, processes for their preparation and pharmaceutical compositions thereof. | |
AU7143196A (en) | Therapeutic applications of animal sera including horse serum in the treatment of aids, cancer, and other viral and bacterial diseases | |
DE69434961D1 (en) | FUNCTION AND ACTIVITY OF THE VIRAL PROTEIN R (VPR) | |
JPH11199495A (en) | Antiallergic agent using enteric capsule | |
JPH0539305A (en) | Immuno suppressive polysaccharide extracted from astragalus membranaceous and pharma- ceutical composition containing same | |
DE19523660A1 (en) | Antigens with characteristics of retro-virus | |
Frejborg et al. | Current landscape in antiviral drug development against herpes simplex virus infections | |
DE69837923T2 (en) | COMPONENT OF BROMELAIN | |
JPH01120284A (en) | Incomplete particle of hiv and production thereof | |
JPS63309200A (en) | Measurement of hiv | |
US5603963A (en) | Method for the treatment of retroviral diseases such as acquired immune deficiency syndrome utilizing (pseudo)halogen complexes of gold(1) | |
AT405608B (en) | METHOD FOR INACTIVATING PATHOGENS, ESPECIALLY VIRUSES, IN A BIOLOGICAL MATERIAL | |
DE60118175T2 (en) | METHOD FOR THE PRODUCTION OF AN IMMUNOTROPIC ANTIVIRAL COMPOSITION | |
UA78673C2 (en) | Use of lactobacillus strains for treating prostate inflammation and benign prostate hyperplasias | |
Panno | Gene therapy: treating disease by repairing genes | |
Emengaha et al. | Gene therapy in the developing countries |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8122 | Nonbinding interest in granting licenses declared | ||
8133 | Disposal/non-payment of the application fee |